HUT76542A - Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy - Google Patents

Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy Download PDF

Info

Publication number
HUT76542A
HUT76542A HU9602536A HU9602536A HUT76542A HU T76542 A HUT76542 A HU T76542A HU 9602536 A HU9602536 A HU 9602536A HU 9602536 A HU9602536 A HU 9602536A HU T76542 A HUT76542 A HU T76542A
Authority
HU
Hungary
Prior art keywords
treatment
glomerular
pharmaceutically acceptable
formula
nephropathy
Prior art date
Application number
HU9602536A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9602536D0 (en
Inventor
Gasparo Marc De
Nigel Levens
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4195481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT76542(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of HU9602536D0 publication Critical patent/HU9602536D0/hu
Publication of HUT76542A publication Critical patent/HUT76542A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9602536A 1994-03-17 1995-03-07 Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy HUT76542A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH80094 1994-03-17

Publications (2)

Publication Number Publication Date
HU9602536D0 HU9602536D0 (en) 1996-11-28
HUT76542A true HUT76542A (en) 1997-09-29

Family

ID=4195481

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602536A HUT76542A (en) 1994-03-17 1995-03-07 Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy

Country Status (12)

Country Link
EP (1) EP0750500A1 (fr)
JP (1) JPH09510225A (fr)
CN (1) CN1143908A (fr)
AU (1) AU1850695A (fr)
BR (1) BR9507086A (fr)
CA (1) CA2184712A1 (fr)
CZ (1) CZ268896A3 (fr)
FI (1) FI963611L (fr)
HU (1) HUT76542A (fr)
PL (1) PL316259A1 (fr)
SK (1) SK117996A3 (fr)
WO (1) WO1995024901A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0883401T3 (da) * 1996-02-29 2003-05-05 Novartis Ag AT1-receptorantagonist til stimulering af apoptose
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1999012534A1 (fr) * 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Regulateurs des recepteurs actives par le proliferateur des peroxisomes
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
NZ522953A (en) 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1454625A1 (fr) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines pour le traitement des néphropaties diabétiques
WO2005046677A2 (fr) * 2003-11-14 2005-05-26 Novartis Ag Utilisation pharmaceutique supplementaire
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
WO2010104485A2 (fr) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Préparations de valsartan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
MX9603999A (es) 1997-12-31
SK117996A3 (en) 1997-03-05
PL316259A1 (en) 1997-01-06
FI963611A7 (fi) 1996-09-13
JPH09510225A (ja) 1997-10-14
EP0750500A1 (fr) 1997-01-02
CN1143908A (zh) 1997-02-26
CZ268896A3 (en) 1997-03-12
BR9507086A (pt) 1997-09-16
AU1850695A (en) 1995-10-03
CA2184712A1 (fr) 1995-09-21
WO1995024901A1 (fr) 1995-09-21
FI963611A0 (fi) 1996-09-13
FI963611L (fi) 1996-09-13
HU9602536D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
HUT76542A (en) Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
UA72587C2 (uk) Комбінація азеластину та сполук, які впливають на дію лейкотриєну, для лікування риніту/кон'юнктивіту, лікарський засіб та спосіб одержання лікарського засобу
AU2017340760B2 (en) Methods of treating acute kidney injury
RS49902B (sr) PREPARATI ZA TRETIRANJE I PREVENCIJU ARTERIJSKE TROMBOZE I KORIŠĆENJE INHIBITORA FAKTORA Xa SAMOG ILI U KOMBINACIJI SA PLATELETNIM ANTIAGREGACIONIM AGENSOM
KR100709528B1 (ko) 혈당콘트롤용 의약조성물
KR101492552B1 (ko) 요 배출 장애 치료제
WO2011141419A1 (fr) Association de l'inhibiteur de la xanthine oxydase fébuxostat et de metformine et son utilisation
WO1993015732A1 (fr) Traitement du glaucome
CN108992456A (zh) 含有香叶木苷硫酸酯衍生物的药物组合物及其应用
AU2011252151A1 (en) Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
ES2360461T3 (es) Agente preventivo o terapéutico para enfermedad inflamatoria del intestino.
CN1305342A (zh) 降低高半胱氨酸和c－反应蛋白水平的方法
WO2010133907A1 (fr) Chélateurs hexadentate utilisables dans le cadre du traitement de la maladie intestinale inflammatoire
JP4525964B2 (ja) 肺高血圧症予防治療剤
JPH0119A (ja) 腎機能改善剤
JP2005516925A5 (fr)
US20040014797A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
JP2772717B2 (ja) 高尿酸血症および痛風治療用の薬剤としてのアモルファス状または結晶状のオキシプリノールのアルカリ塩およびアルカリ土類塩
KR960014874B1 (ko) 요산 배출용 조성물
MXPA96003999A (en) Treatment of diabetic nephropathy with valsar
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
JP2621382B2 (ja) 尿酸排泄剤
CN112512526A (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
JPH10330265A (ja) 肝疾患治療剤
CN117959290A (zh) N-苄基-5/6-甲酰氨基吲哚-2-羧酸衍生物在制备防治多囊卵巢综合征药物的应用

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: NOVARTIS AG., CH

DFD9 Temporary protection cancelled due to non-payment of fee